Immutep TACTI-002 Data Presentation at the AACR Virtual Annual Meeting 2020

SYDNEY, Australia, April 14, 2020 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, announced that interim Phase II TACTI-002 clinical data has been selected for a poster short talk presentation as part of the high-impact paper presentation program at the American Association for Cancer Research (AACR) Virtual Annual Meeting, scheduled for 27 and 28 April.

This presentation was originally accepted as a late-breaking poster for the AACR Annual Meeting prior to the event being rescheduled as two virtual events due to the ongoing COVID-19 pandemic, including AACR Virtual Annual Meetings I and II. The data in this presentation relates to Immutep’s lead product candidate, eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3 protein based on the LAG-3 immune control mechanism, as part of a combination treatment with pembrolizumab, an anti-PD-1 therapy.

Presentation Details:

The abstract title was published today on the AACR website at https://www.abstractsonline.com/pp8/#!/9045/presentation/10803.

The submitted abstract and the virtual poster presentation will also be accessible on Immutep’s website at www.immutep.com/investors-media/presentations.html on the day of the poster presentation.

TACTI-002 is being conducted in collaboration with Merck & Co., Inc., Kenilworth, NJ, USA (known as “MSD” outside the United States and Canada). It is evaluating the combination of efti with MSD’s KEYTRUDA® (pembrolizumab) in up to 109 patients with second line HNSCC or NSCLC in first and second line.

About Immutep

Further information can be found on the Company’s website www.immutep.com or by contacting:

Australian Investors/Media:
Catherine Strong, Citadel-MAGNUS
+61 (0)406 759 268; [email protected]

U.S. Media:
Garth Russell, LifeSci Advisors
+1 (646) 876-3613; [email protected]